Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06598969 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Name: TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia — clinical trial record (NCT06598969)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: TMLI-MA

StatusNot Yet Recruiting

PhasePhase 2

SponsorFundación Pública Andaluza para la gestión de la Investigación en Sevilla

Started2024-12-30

View on ClinicalTrials.gov ↗

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

27 trials monitored

See all monitored trials

Leukemia

2,553 trials monitored

See 134 trials at risk

Acute Myeloid Leukemia (AML)

1,196 trials monitored

See 63 trials at risk

Myelodysplastic Syndromes (MDS)

685 trials monitored

See 40 trials at risk

Single-arm, single-center phase II trial to evaluate the antileukemic activity and safety/tolerability of TMLI/cyclophosphamide and etoposide conditioning regimen followed by allogeneic hematopoietic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute myeloid leukemia.

Trial Details

NCT Number	NCT06598969
Lead Sponsor	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Conditions	Myelodysplastic Syndromes, Myeloid Leukemia, Acute
Enrollment	58 participants
Start Date	2024-12-30
Primary Completion	2026-12-30 (estimated)
Study Completion	2028-12-30 (estimated)
Updated on ClinicalTrials.gov	2024-09-19